FDA Approves Opdivo for Treatment of Bladder Cancer
The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or […] The post FDA Approves Opdivo for Treatment of Bladder Cancer...
View ArticleAdvances in Management of Cervical Cancer
Cervical cancer is the third most common female cancer and the most common cause of death from gynecologic cancers worldwide. […] The post Advances in Management of Cervical Cancer appeared first on .
View ArticleManaging Inflammatory Arthritis From Checkpoint Inhibitors
Inflammatory arthritis is a newly recognized side effect associated with immune checkpoint blockade, an increasingly used treatment for a number […] The post Managing Inflammatory Arthritis From...
View ArticleFirst-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung...
Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are […] The post First-Line Immunotherapy Treatment Can Improve Survival...
View ArticleOpdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma
A clinical trial evaluating Opdivo (nivolumab) versus Yervoy (ipilimumab) in patients with stage IIIb/c or stage IV melanoma who are at high risk […] The post Opdivo Proves Superior to Yervoy for...
View ArticleAnti-LAG-3 in Combination with Opdivo Show Activity in Patients with Melanoma...
For some cancers immunotherapy is becoming a standard of care, but there are growing numbers of patients who are refractory […] The post Anti-LAG-3 in Combination with Opdivo Show Activity in Patients...
View ArticleOpdivo in Combination with Yervo Demonstrates Improved Overall Survival for...
A Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or metastatic renal cell […] The post Opdivo in Combination with Yervo Demonstrates...
View ArticleOpdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma
Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or […] The post Opdivo Proves Superior to Yervoy for Adjuvant...
View ArticleImfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer
Immunotherapy could be the new standard of care in patients with non-small cell lung cancer (NSCLC). The novel immunotherapy checkpoint […] The post Imfinzi Improves Survival in Stage 3 Non Small Cell...
View ArticleFDA Approves Checkpoint Inhibitor Targeted Immunotherapy for Treatment of...
The U.S. Food and Drug Administration recently approved two precision cancer medicines for the treatment of colorectal cancer with a […] The post FDA Approves Checkpoint Inhibitor Targeted...
View ArticleFirst Line Combination Therapy Improves Progression-Free Survival In Advanced...
A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment […] The post First Line Combination...
View ArticleNew Immunotherapy for Lung Cancer Shows Promise of Success
Novel combination of drugs is a huge step forward in cancer treatment In a groundbreaking development, results from a recent […] The post New Immunotherapy for Lung Cancer Shows Promise of Success...
View ArticleFDA Approves Opdivo plus Yervoy Combination for Advanced Kidney Cancer
CancerConnect News: The Food and Drug Administration granted approvals to Opdivo (nivolumab) and Yervoy (ipilimumab) in combination for the treatment […] The post FDA Approves Opdivo plus Yervoy...
View Article
